BSEM Stock Overview
A life sciences corporation, focuses on discovering, developing, and producing pharmaceutical and regenerative medicine products and services. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 5/6 |
| Past Performance | 4/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
BioStem Technologies, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$13.90 |
| 52 Week High | US$28.26 |
| 52 Week Low | US$2.34 |
| Beta | 1.78 |
| 11 Month Change | 16.32% |
| 3 Month Change | 32.38% |
| 1 Year Change | 363.33% |
| 33 Year Change | 1,211.32% |
| 5 Year Change | 595.00% |
| Change since IPO | -98.42% |
Recent News & Updates
Recent updates
Shareholder Returns
| BSEM | US Pharmaceuticals | US Market | |
|---|---|---|---|
| 7D | -43.8% | -5.7% | -2.1% |
| 1Y | 363.3% | 9.0% | 29.6% |
Return vs Industry: BSEM exceeded the US Pharmaceuticals industry which returned 9% over the past year.
Return vs Market: BSEM exceeded the US Market which returned 29.6% over the past year.
Price Volatility
| BSEM volatility | |
|---|---|
| BSEM Average Weekly Movement | 14.8% |
| Pharmaceuticals Industry Average Movement | 9.7% |
| Market Average Movement | 6.2% |
| 10% most volatile stocks in US Market | 15.5% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: BSEM's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: BSEM's weekly volatility (15%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2006 | n/a | Jason Matuszewski | www.biostemtechnologies.com |
BioStem Technologies, Inc., a life sciences corporation, focuses on discovering, developing, and producing pharmaceutical and regenerative medicine products and services. It develops various biologic stem cell based alternative products, as a treatment for ailments, such as joint pain, tendon and ligament injuries, neurodegenerative, and autoimmune diseases. The company is also engages in the repackaging and distribution of active pharmaceutical ingredients and other pharmaceutical compounding supplies; and develops and markets nutraceutical products under the Dr. Dave’s Best and Nesvik Organics brands, as well as other non-proprietary products in the United States and internationally.
BioStem Technologies, Inc. Fundamentals Summary
| BSEM fundamental statistics | |
|---|---|
| Market cap | US$231.00m |
| Earnings (TTM) | US$15.85m |
| Revenue (TTM) | US$210.49m |
14.6x
P/E Ratio1.1x
P/S RatioIs BSEM overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| BSEM income statement (TTM) | |
|---|---|
| Revenue | US$210.49m |
| Cost of Revenue | US$10.84m |
| Gross Profit | US$199.65m |
| Other Expenses | US$183.80m |
| Earnings | US$15.85m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.95 |
| Gross Margin | 94.85% |
| Net Profit Margin | 7.53% |
| Debt/Equity Ratio | 18.3% |
How did BSEM perform over the long term?
See historical performance and comparison